190 related articles for article (PubMed ID: 24832153)
1. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.
De Remigis A; de Gruijl TD; Uram JN; Tzou SC; Iwama S; Talor MV; Armstrong TD; Santegoets SJ; Slovin SF; Zheng L; Laheru DA; Jaffee EM; Gerritsen WR; van den Eertwegh AJ; Le DT; Caturegli P
Int J Cancer; 2015 Jan; 136(1):127-37. PubMed ID: 24832153
[TBL] [Abstract][Full Text] [Related]
2. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Le DT; Lutz E; Uram JN; Sugar EA; Onners B; Solt S; Zheng L; Diaz LA; Donehower RC; Jaffee EM; Laheru DA
J Immunother; 2013 Sep; 36(7):382-9. PubMed ID: 23924790
[TBL] [Abstract][Full Text] [Related]
4. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
[TBL] [Abstract][Full Text] [Related]
5. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
Wada S; Jackson CM; Yoshimura K; Yen HR; Getnet D; Harris TJ; Goldberg MV; Bruno TC; Grosso JF; Durham N; Netto GJ; Pardoll DM; Drake CG
J Transl Med; 2013 Apr; 11():89. PubMed ID: 23557194
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
8. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
[TBL] [Abstract][Full Text] [Related]
9. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
10. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
[TBL] [Abstract][Full Text] [Related]
11. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
Curran MA; Allison JP
Cancer Res; 2009 Oct; 69(19):7747-55. PubMed ID: 19738077
[TBL] [Abstract][Full Text] [Related]
12. Epitopes on thyroglobulin: a study of patients with thyroid disease.
Caturegli P; Mariotti S; Kuppers RC; Burek CL; Pinchera A; Rose NR
Autoimmunity; 1994; 18(1):41-9. PubMed ID: 7528064
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
14. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.
Jhaveri DT; Kim MS; Thompson ED; Huang L; Sharma R; Klein AP; Zheng L; Le DT; Laheru DA; Pandey A; Jaffee EM; Anders RA
Cancer Immunol Res; 2016 Mar; 4(3):225-33. PubMed ID: 26842750
[TBL] [Abstract][Full Text] [Related]
15. Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes.
Latrofa F; Phillips M; Rapoport B; McLachlan SM
J Clin Endocrinol Metab; 2004 Oct; 89(10):5116-23. PubMed ID: 15472215
[TBL] [Abstract][Full Text] [Related]
16. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
17. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
18. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
[TBL] [Abstract][Full Text] [Related]
19. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
20. Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer.
Bajor DL; Vonderheide RH
J Immunother; 2013 Sep; 36(7):362-4. PubMed ID: 23924787
[No Abstract] [Full Text] [Related]
[Next] [New Search]
